ATE469353T1 - Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen - Google Patents
Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungenInfo
- Publication number
- ATE469353T1 ATE469353T1 AT06763552T AT06763552T ATE469353T1 AT E469353 T1 ATE469353 T1 AT E469353T1 AT 06763552 T AT06763552 T AT 06763552T AT 06763552 T AT06763552 T AT 06763552T AT E469353 T1 ATE469353 T1 AT E469353T1
- Authority
- AT
- Austria
- Prior art keywords
- proanp
- probnp
- level
- cardiac
- increased level
- Prior art date
Links
- 208000019622 heart disease Diseases 0.000 title abstract 5
- 230000001154 acute effect Effects 0.000 abstract 4
- 230000000747 cardiac effect Effects 0.000 abstract 4
- 208000020446 Cardiac disease Diseases 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 abstract 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 abstract 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 abstract 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 abstract 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05012196A EP1731910A1 (de) | 2005-06-07 | 2005-06-07 | Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten |
| PCT/EP2006/062957 WO2006131529A1 (en) | 2005-06-07 | 2006-06-07 | Use of nt-proanp and nt-probnp for diagnosing cardiac diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469353T1 true ATE469353T1 (de) | 2010-06-15 |
Family
ID=34937270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06763552T ATE469353T1 (de) | 2005-06-07 | 2006-06-07 | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7608418B2 (de) |
| EP (2) | EP1731910A1 (de) |
| JP (1) | JP4828600B2 (de) |
| CN (1) | CN101194167A (de) |
| AT (1) | ATE469353T1 (de) |
| CA (1) | CA2607264A1 (de) |
| DE (1) | DE602006014535D1 (de) |
| WO (1) | WO2006131529A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US7670769B2 (en) | 2002-05-09 | 2010-03-02 | The Brigham And Women's Hospital, Inc. | IL1RL-1 as a cardiovascular disease marker and therapeutic target |
| ES2344993T3 (es) * | 2006-03-24 | 2010-09-13 | F. Hoffmann-La Roche Ag | Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos. |
| PL2386860T4 (pl) | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Przewidywanie śmiertelności i wykrywanie poważnej choroby |
| PT2021796E (pt) | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
| NZ576061A (en) | 2006-09-07 | 2013-02-22 | Otago Innovation Ltd | Biomarkers |
| JP2010517023A (ja) * | 2007-01-25 | 2010-05-20 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全の評価におけるｉｇｆｂｐ−７の使用 |
| EP1970709B1 (de) * | 2007-03-06 | 2013-07-10 | Roche Diagnostics GmbH | Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs |
| DE102007010834A1 (de) * | 2007-03-03 | 2008-09-04 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten |
| DE102007022367A1 (de) * | 2007-05-07 | 2008-11-20 | B.R.A.H.M.S Ag | Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten |
| EP2210111A1 (de) * | 2007-10-10 | 2010-07-28 | Roche Diagnostics GmbH | Natriuretisches peptid/troponin-verhältnis zur beurteilung bereits vorhandener myokard-fehlfunktion bei patienten mit akutem koronarsyndrom |
| ES2457529T3 (es) | 2007-10-10 | 2014-04-28 | F. Hoffmann-La Roche Ag | Medios y métodos para controlar el infarto de miocardio y su tratamiento |
| WO2009104974A2 (en) * | 2008-02-22 | 2009-08-27 | Christopher Joseph Pemberton | Biomarkers |
| JP5818440B2 (ja) | 2008-03-12 | 2015-11-18 | オタゴ イノベーション リミテッド | バイオマーカー |
| CA2715921A1 (en) | 2008-03-12 | 2009-09-17 | Otago Innovation Limited | Biomarkers |
| SI2269063T1 (sl) | 2008-04-18 | 2014-01-31 | Critical Care Diagnostics, Inc. | Napoved tveganja večjih neugodnih pojavov na srcu |
| EP2318844A1 (de) * | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz |
| WO2010077654A1 (en) * | 2008-12-08 | 2010-07-08 | Biosite Incorporated | Combined natriuretic peptide assays |
| BR112012011230A2 (pt) * | 2009-11-13 | 2016-04-05 | Bg Medicine Inc | fatores de risco e previsão de infarto do miocárdio |
| CA2780965C (en) * | 2009-11-27 | 2019-06-04 | F. Hoffmann-La Roche Ag | Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction |
| US20110306148A1 (en) | 2010-06-14 | 2011-12-15 | Siemens Healthcare Diagnostics Inc. | Composition for use as an assay reagent |
| AU2011282245B2 (en) | 2010-07-19 | 2017-09-28 | Otago Innovation Limited | Signal biomarkers |
| CN106940375B (zh) | 2011-03-17 | 2019-03-08 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| US9128103B2 (en) * | 2011-07-28 | 2015-09-08 | B.R.A.H.M.S. Gmbh | Mid-regional pro-atrial natriuretic peptide (pro-ANP) for the identification of patients with atrial fibrillation with an onset of less than 48 hours ago |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP3088900B1 (de) | 2011-10-17 | 2020-08-12 | Roche Diagniostics GmbH | Troponin als marker für intermittierendes vorhofflimmern |
| EP2594940A1 (de) * | 2011-11-16 | 2013-05-22 | Koninklijke Philips Electronics N.V. | Partikelabstoßung zur Verbesserung des Oberflächenkontakts in Magnetpartikelimmuntests |
| EP2786154B1 (de) * | 2011-12-01 | 2017-11-01 | Roche Diagnostics GmbH | Nt-pro-anp und nt-pro-bnp zur diagnose eines schlaganfalls |
| US10114028B2 (en) | 2012-03-20 | 2018-10-30 | Upstream Medical Technologies Limited | Biomarkers for pneumonia and acute decompensated heart failure |
| HK1212057A1 (en) | 2012-08-21 | 2016-06-03 | 重症监护诊断股份有限公司 | Multimarker risk stratification |
| CN103304665A (zh) * | 2013-05-21 | 2013-09-18 | 上海贝西生物科技有限公司 | 一种抗氨基末端脑利钠肽前体单克隆抗体及其应用 |
| US20170049856A1 (en) * | 2014-04-28 | 2017-02-23 | Juventas Therapeutics, Inc. | Sdf-1 delivery for treating advanced ischemic cardiomyopathy |
| CN105085659B (zh) * | 2014-05-20 | 2021-02-19 | 深圳大学 | 一种重组利钠肽及其制备方法 |
| BR112020005682A2 (pt) * | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
| US6461828B1 (en) * | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
| US7432107B2 (en) * | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
| EP1859283A1 (de) * | 2005-02-17 | 2007-11-28 | F. Hoffmann-Roche AG | Verwendung des nt-proanp/nt-probnp-verhältnisses zur diagnose von herzfehlfunktionen |
| ES2657087T3 (es) * | 2005-07-29 | 2018-03-01 | Koninklijke Philips N.V. | Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas |
| PL2386860T4 (pl) * | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Przewidywanie śmiertelności i wykrywanie poważnej choroby |
| EP1882945A1 (de) * | 2006-07-28 | 2008-01-30 | F.Hoffmann-La Roche Ag | Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot |
| ATE449966T1 (de) * | 2006-09-15 | 2009-12-15 | Hoffmann La Roche | Biochemische marker für akute lungenembolie |
| DE602006015964D1 (de) * | 2006-09-20 | 2010-09-16 | Roche Diagnostics Gmbh | Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion |
| US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
-
2005
- 2005-06-07 EP EP05012196A patent/EP1731910A1/de not_active Withdrawn
-
2006
- 2006-06-07 AT AT06763552T patent/ATE469353T1/de not_active IP Right Cessation
- 2006-06-07 CN CNA2006800204604A patent/CN101194167A/zh active Pending
- 2006-06-07 CA CA002607264A patent/CA2607264A1/en not_active Abandoned
- 2006-06-07 WO PCT/EP2006/062957 patent/WO2006131529A1/en not_active Ceased
- 2006-06-07 EP EP06763552A patent/EP1889073B1/de not_active Not-in-force
- 2006-06-07 JP JP2008515210A patent/JP4828600B2/ja not_active Expired - Fee Related
- 2006-06-07 DE DE602006014535T patent/DE602006014535D1/de active Active
-
2007
- 2007-11-27 US US11/945,309 patent/US7608418B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006131529A1 (en) | 2006-12-14 |
| CN101194167A (zh) | 2008-06-04 |
| JP4828600B2 (ja) | 2011-11-30 |
| JP2008542778A (ja) | 2008-11-27 |
| US20090042228A1 (en) | 2009-02-12 |
| US7608418B2 (en) | 2009-10-27 |
| EP1889073A1 (de) | 2008-02-20 |
| EP1889073B1 (de) | 2010-05-26 |
| EP1731910A1 (de) | 2006-12-13 |
| CA2607264A1 (en) | 2006-12-14 |
| DE602006014535D1 (de) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469353T1 (de) | Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen | |
| Sugimoto et al. | Cardiac biomarkers in children with congenital heart disease | |
| DE602006011896D1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| DE602005002500D1 (de) | Kombination von Markern für Diabetes Typ 1 und 2 | |
| JP2007523324A5 (de) | ||
| EP1922325A4 (de) | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen | |
| RU2014145259A (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| Cai et al. | Predictive value of phosphorylated axonal neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage | |
| ES2954321T3 (es) | Proteína 3 de unión a ácidos grasos para la evaluación de fibrilación auricular (FA) | |
| ATE537454T1 (de) | Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15 | |
| NO20050186L (no) | Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser | |
| WO2009087190A1 (en) | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 | |
| DE602005001299D1 (de) | Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes | |
| JP5715636B2 (ja) | 循環系事象と虚血性事象を鑑別するためのＮＴ−ｐｒｏＡＮＰおよびＳＦｌｔ−１ | |
| JP2009537797A (ja) | 神経変性疾患の診断及び早期診断のためのｉｎｖｉｔｒｏ方法 | |
| ATE483982T1 (de) | Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen | |
| DE602007008370D1 (de) | Verfahren zur Detektion der in-vivo-Aktivität von Neurotrypsin, Verwendung des Verfahrens und Verwendung des C-terminal 22-kDa-Fragments als Biomarker bei der Diagnose und Überwachung von Störungen im Zusammenhang mit Neurotrypsin | |
| Meyer et al. | Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors | |
| JP2019509500A (ja) | 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング | |
| DE602006002490D1 (de) | Verfahren zur diagnose von tumoren | |
| DE502004012230D1 (de) | Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i | |
| DE602006015964D1 (de) | Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion | |
| US20230176077A1 (en) | Ret (rearranged during transfection) for the assessment of stroke | |
| ES2706539T3 (es) | Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo | |
| ES2657087T3 (es) | Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |